1 January 2019 in Clinical Laboratory
This study aimed to evaluate the relationship of serum vitronectin and integrin alpha V beta 3 (αvβ3) levels with various clinicopathological parameters of breast cancer and to assess the diagnostic value of these markers alone or in combination with the conventional breast cancer biomarker CA15.3. This study included 50 early diagnosed stage I - II primary breast cancer patients, 20 patients with fibroadenoma benign lesions, and 20 apparently normal healthy controls. Integrin αVβ3, vitronectin, and CA15.3 levels were measured using ELISA technique. Serum levels of integrin αVβ3 and vitronectin were significantly higher in the malignant group than those in the benign group and the control group with (p < 0.001). Significant positive correlation between integrin αvβ3 and vitronectin concentrations was found. Both markers showed significant statistically difference with lymph node, histological grade, tumor stage, and tumor size (p < 0.05). Integrin αvβ3 exhibited the highest sensitivity (70%) and specificity (68%), then vitronectin with 67% and 68%, respectively, followed by CA15.3 showing the least sensitivity and specificity (65% and 62%, respectively). All assessed parameters revealed comparable area under the receiver-operating characteristic curve (AUC) 95% confidence interval (CI) range of 0.581 - 0.822. Integrin αvβ3 is a promising biomarker alone or in combination with vitronectin and CA15.3 for diagnosis and prognosis of early stage breast cancer.
12 May 2022 in Zagazig University Medical Journal
Background: Hypercoagulable state is associated with thalassemic children with increased risk of thromboembolic events ,There are multiple factors are contributing to hypercoagulable state in thalassemia patient.Aim of the study: To assesses the prothrombin G20210A gene polymorphism in Egyptian thalassemic children being additional risk factor for thromboembolism in thalssemic children .Methods: This is a case control study. It included 40 thalassemic patients with thromboembolic manifistation and 40 healthy controls. The prothrombin gene polymorphism was identified using a restriction fragment length polymerase chain reaction (RFLP PCR).Results: No Significant difference in prothrombin G20210A genotype between Thalssemic patient with thrombotic manifistation and controls regarding allele and genotype distributions. (OR 3.2 , 95 % CI 0.57–17.89 and p=0.082 for AA genotype ). A allele was significantly related to cases (25% in cases in comparison to 12.5% in controls).Conclusion: prothrombin gene polymorphism has no role predisposition to thalassemic coagulability in thalassemic Egyptian children.